# Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

> **NCT00270894** · PHASE2 · COMPLETED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 30 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** epirubicin
- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT00270894
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270894, "Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00270894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*